Neoadjuvant versus adjuvant chemotherapy in luminal B-like breast cancer: a subset analysis of the CANTO study.

Fiche publication

Date publication

décembre 2026

Journal

ESMO real world data and digital oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie

Tous les auteurs :
Gaillard T, Cottu P, Tredan O, Martin AL, Gaudin C, Bertaut A, Cheymol C, Kaderbhai C, Cherifi F, Campone M, Mouret-Reynier MA, Di-Meglio A, Reyal F, Hamy-Petit AS, Laas E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42903650

Résumé

The benefit of neoadjuvant chemotherapy (NAC) in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) remains uncertain, given low pathologically documented complete response (pCR) rates and limited long-term comparative data. We compared overall survival (OS) between NAC and adjuvant chemotherapy (AC) in luminal B-like breast cancer treated in routine practice.